Oral biologics is a novel category of drugs and used in treatment of various disease such as diabetes, arthritis and many more. Oral drug delivery is an easiest and mostly preferred route of drug administration for various disease.
Increasing preference for oral drugs among patient, as the oral drugs more convenient to administer. This is a major factor driving growth of the oral biologics market across the globe. Also, increasing oral drug development by leading manufacturers is expected to support growth of the market in the near future.
Moreover, increasing strategic moves among leading players of the market is another factor driving growth of the market. For instance, in 2016, MedImmune, LLC collaborated with Rani Therapeutics for development of oral drugs for metabolic disease.
The global oral biologics market has been segmented on the basis of therapy, disease indication and region.
On the basis of therapy type, the global oral biologics market has been segmented into lymphocyte modulators, interleukin inhibitors, and Tumor necrosis factor-alpha inhibitors.
On the basis of disease indication, the target market is segmented into asthma, crohn’s disease, carcinoma, arthritis, diabetes, multiple myeloma, enterocolitis, multiple sclerosis, sarcoma, psoriasis, and others.
Request Sample Copy of the Report: https://marketresearch.biz/report/oral-biologics-market/request-sample/
Regional segmentation includes North America, Europe, Latin America, Asia Pacific and Middle East & Africa. North America contributes major market share and expected to maintain its dominance over the forecast period owing to increasing drug approvals for oral biologics in the region. Europe is expected to contribute second largest market share followed by Asia Pacific.
Some prominent players in the global oral biologics market includes Eli Lilly and Co., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Rani Therapeutics, LLC and Novo Nordisk.